Skip to main content
. Author manuscript; available in PMC: 2022 Aug 3.
Published in final edited form as: J Am Coll Cardiol. 2021 Aug 3;78(5):513–531. doi: 10.1016/j.jacc.2021.05.035

Figure 6: Weight Loss Induced by SGLT2 Inhibitors and GLP1-RA and MACE/Mortality.

Figure 6:

Relationship between reported difference in average body weight loss (BWL, in kg) between the active treatment vs. placebo and relative risk reduction (RRR) of 3-point major adverse cardiovascular events (MACE) (left panel) or total mortality (right panel) from major adverse cardiovascular outcome trials with sodium-glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with type 2 diabetes (T2D). CKD: chronic kidney disease; CVD: cardiovascular disease; HF: heart failure. * Difference in average weight loss estimated from data reported in a graph. † P <0.05 between the active vs. placebo treatment groups.